SCHEMBL3100314

SCHEMBL3100314

Cc1ccc(C(C)(C)C)c(OC2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 9/20 0.52
PDE4B Q07343 3/20 0.52
PDE4D Q08499 3/20 0.52
PDE4A P27815 2/20 0.52
PDE4C Q08493 2/20 0.52
NPBWR1 P48145 1/20 0.49
MCHR1 Q99705 1/20 0.49
KDM1A O60341 1/20 0.48
RBP4 P02753 1/20 0.48
KMT2A Q03164 1/20 0.48
EPHX2 P34913 1/20 0.48
TOP2A P11388 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103045 0.86 RBP4 (0.63) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL14453583 0.86 NPBWR1 (0.57) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL7727287 0.86 NPBWR1 (0.57) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL3164585 0.85 GPR119 (0.51) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL4282196 0.84 GPR119 (0.50) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL4282199 0.83 PDE4B (0.49) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL3114304 0.82 RBP4 (0.55) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL3094603 0.82 GPR119 (0.58) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL25639842 0.81 GPR119 (0.53) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL3103705 0.81 RBP4 (0.60) PDE4BPDE4DPDE4APDE4CRBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202223-B1 HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT TAKEDA PHARMACEUTICALS CO (JP) 2017-01-25 EP disclosed
EP-2202223-B1 HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT TAKEDA PHARMACEUTICALS CO (JP) 2017-01-25 EP disclosed
US-9487509-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-08 US disclosed
US-9487509-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-08 US disclosed
US-9487509-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-08 US disclosed
US-20140066420-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-06 US disclosed
US-20140066420-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-06 US disclosed
US-20140066420-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-06 US disclosed
US-8586571-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-19 US disclosed
US-8586571-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-19 US disclosed
US-20100292206-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-18 US disclosed
US-20100292206-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-18 US disclosed
US-20100292206-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-18 US disclosed
EP-2202223-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066420-A1 HETEROCYCLIC COMPOUND RBP4, RBP1, RAVER1 GPR119 743/4885PDE4B 816/4885PDE4D 1717/4885
US-20100292206-A1 HETEROCYCLIC COMPOUND RBP4, RBP1, RAVER1 GPR119 743/4885PDE4B 816/4885PDE4D 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.